$CRTX News

Last published 4y ago

4y agoCRTX QNCXCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022Business WireNew ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunct
4y agoCRTXCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588Business WireOnce daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today
4y agoCRTXCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, fo
4y agoCRTXCortexyme Appoints June Bray to its Board of DirectorsBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process exper
4y agoCRTXCortexyme Appoints Dr. Philip Low to Its Board of DirectorsBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted
4y agoCRTXCortexyme Successfully Completes Acquisition of NovosteoBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately
4y agoCRTXCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4th International Confe
4y agoCRTXCortexyme Announces Agreement to Acquire NovosteoBusiness WireExpanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined compan
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoBRQS CRTX NAT NOK+1Thinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker?PR NewswireNEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRTX, BRQS, SNDL, NOK, and NAT.
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, April 21, 2022 (GLOBE NEWSWIRE) -- Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm BOSTON -- Block & Leviton is investigating Cortexyme
4y agoCRTXCortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer's PopulationBusiness WireTarget engagement and biomarker data expands understanding of the role of P. gingivalis and the potential benefit of lysine gingipain inhibition Biomarker data and correlations to clinical outcomes consistent with the gingipain hypothesis Cortexym
4y agoCRTXCortexyme Appoints Marwan Sabbagh, MD, to its Board of DirectorsBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN,
4y agoCRTXCortexyme to Present New GAIN Trial Data at AD/PD 2022Business WireNew data expands evidence base of role of P. gingivalis in Alzheimer's disease Discussion to include new biomarker results and correlations between biomarkers and clinical outcomes Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical
4y agoCRTXCortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant DisordersBusiness WireFirst-in-class lysine gingipain inhibitor, atuzaginstat, has the potential to reduce the malignant progression of oral potentially malignant disorders (OPMD) In vitro study results demonstrate that PD-L1 is induced by P. gingivalis and can be blocked
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / March 8, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more abou
4y agoCRTXCortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588Business WireCOR588 well-tolerated in all dose cohorts Human pharmacokinetics support once daily oral dosing Multiple ascending dose data expected in the second quarter of 2022 Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pionee
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / March 1, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more abou
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / February 24, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / February 22, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / February 17, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / February 15, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme, Inc. Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmACCESS NewswireBOSTON, MA / ACCESSWIRE / February 11, 2022 / Block & Leviton is investigating Cortexyme, Inc. (NASDAQ:CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more
4y agoCRTXCortexyme Announces Pipeline Update and Anticipated 2022 MilestonesBusiness WireNext generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimer's development Additional pipeline includes therapeutics in development for coronavirus infection, periodont
4y agoCRTXCortexyme Announces Change in Executive Leadership TeamBusiness WireChristopher Lowe appointed interim chief executive officer David Lamond named chairman of the board Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced t
4y agoCRTXCortexyme Announces Clinical Hold on Atuzaginstat's Investigational New Drug ApplicationBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 pla
4y agoCRTXCortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30thBusiness WireCortexyme, Inc. (NASDAQ:CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, begi
5y agoCRTXCortexyme's Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer's Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021Business WireEvidence supports P. gingivalis as a driver of Alzheimer's in easily identified patient population Successful identification of target population and therapeutic dose inform next steps Cortexyme, Inc. (NASDAQ:CRTX) will present additional data fro
5y agoCRTXCortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11thBusiness WireCortexyme, Inc. (NASDAQ:CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting's Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m.
5y agoBBIG BNTX CRTX ENPH+1Thinking about buying stock in Inspira Technologies, Vinco Ventures, Cortexyme, Enphase Energy, or BioNTech?PR NewswireNEW YORK, Oct. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IINN, BBIG, CRTX, ENPH, and BNTX.
5y agoCRTXCortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease ProgressionBusiness WireIn overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Cl
5y agoMYMD CRTX HYFM AZEK+1Cramer's lightning round: Azek Company is a great stock hereCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
5y agoCRTXCortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease at CTAD 2021Business WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer's disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14th Clinical Trials on Alzhei
5y agoCRTXCortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588Business WireFirst participants dosed in clinical trial of second-generation gingipain inhibitor differentiated by novel compound properties and anticipated once daily administration Clinical advancement of pipeline delivers on commitment to bring innovation to
5y agoCRTXCortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13thBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Casey Lynch, chief executive offi
5y agoCRTXCortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer's Disease at Annual Biomarkers for Alzheimer's Disease SummitBusiness WireGAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer's pathologies Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with t
5y agoCRTXCortexyme to Present at Annual Biomarkers for Alzheimer's Disease SummitBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, will participate as a featured speaker covering
5y agoCRTXCortexyme Provides Business Update and Reports Second Quarter 2021 ResultsBusiness WireGAIN Trial top-line data for disease modification in Alzheimer's expected by mid-November 2021 Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021 Current cash position sufficient to fund operations throu
5y agoCRTXCortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer's Disease at AAIC 2021Business WireNew GAIN Trial baseline data demonstrates majority of patients have elevated Von Willebrand factor and alpha-2-macroglobulin Cortexyme to host AAIC symposium titled "Getting to the Root Cause of Alzheimer's Disease: An Innovative, Upstream Approach
5y agoCRTXCortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus InfectionBusiness WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpr
5y agoCRTXCortexyme to Present New Data at AAIC 2021Business WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will present two post
5y agoCRTXCortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021Business WireLeading drug candidate penetrates and disrupts bacterial biofilms, a key feature for efficacy in treating P. gingivalis driven disease Atuzaginstat reverses alveolar bone loss in mice after oral P. gingivalis infection at doses relevant for therapeut
5y agoCRTXCortexyme to Host Symposium at AAIC 2021Business Wire"Getting to the Root Cause of Alzheimer's Disease: An Innovative, Upstream Approach for Disease Modification" Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter
5y agoCRTXCortexyme to Host Two-Part Key Opinion Leader Webinar Series on AtuzaginstatBusiness WirePart 1 to be held Friday July 23 at 10:00 a.m. ET: Innovation in Periodontal Disease – A Major Unmet Medical Need Part 2 to be held Friday July 30 at 10:00 a.m. ET: Innovation in Alzheimer's Disease – Getting to the Root Cause of Neurodegeneratio
5y agoCRTXCortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual MeetingBusiness WireBaseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021 Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline da
5y agoCRTXCortexyme to Present at Investor Conferences in June 2021Business WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company's
5y agoCRTXCortexyme Provides Business Update and Reports First Quarter 2021 ResultsBusiness WireTop-line data from 643-subject Alzheimer's disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021 COR588 on trac
5y agoCRTXCortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021Business WireCortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company'
5y agoCRTXCortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, co-founder, and chair, will participate in a fireside chat at the Stifel ...